When I first walked into a urology conference in 2006, I overheard a frustrated clinician say, “I’ve spent three years trying to help a patient who pees every 45 minutes and nothing’s worked.” Back then, sacral neuromodulation (SNM) was still a niche procedure, reserved only for patients who’d exhausted every other option and failed dozens of drug and behavioral therapies. Today, as a supplier in this space, I see how far we’ve come—from a handful of early prototypes to a life-changing treatment that’s now accessible to millions. The history of SNM isn’t just a list of tech milestones; it’s a story of clinicians fighting for patients, engineers refining untested ideas, and suppliers like us bridging the gap between lab breakthroughs and real-world care. Sacral Neuromodulation
Let’s rewind to the 1970s, when the groundwork for SNM was laid. The story starts not in a urology lab, but in a neurosurgical practice in Belgium. Dr. Jef Pannek, a pioneer in neuromodulation for spinal cord injuries, was experimenting with how electrical signals could interfere with abnormal nerve function. At the time, spinal cord stimulators were being used to treat chronic pain, but Pannek noticed something unusual: patients who had these devices reported unexpected improvements in bladder control, even when the stimulator was targeting a different area. That observation planted a seed. He began small-scale studies, implanting temporary wires near the sacral nerve roots in patients with overactive bladder (OAB) and urinary incontinence. The preliminary results were too promising to ignore—70% of patients reported reduced urgency and fewer accidents—but the medical community was skeptical. Neuromodulation for the bladder sounded more science fiction than medicine, and large-scale clinical trials were still years away.
The 1980s brought the first pivotal shift, thanks to a team at the University of California, San Francisco (UCSF), led by Dr. William Jonas. Jonas built on Pannek’s early work, focusing specifically on the sacral nerves— the bundle of nerves at the base of the spine that controls bladder, bowel, and pelvic floor function. His team developed a temporary test procedure, where a thin wire was placed near the S3 sacral nerve (the largest and most clinically impactful of the sacral roots) for a 1- to 2-week trial. If patients reported a 50% or greater reduction in incontinence episodes, they qualified for a permanent implant. This test phase was a game-changer; it allowed clinicians to predict who would benefit from the long-term device, eliminating the guesswork that had plagued earlier attempts. In 1981, Jonas published his first paper on successful permanent implantation, marking the first formal recognition of SNM as a viable treatment. By the end of the decade, the FDA had approved the first temporary test leads, paving the way for full device approval.
The 1990s were SNM’s coming-of-age decade, both in clinical acceptance and commercial development. In 1997, the FDA granted premarket approval (PMA) for the first permanent sacral neuromodulation system, manufactured by a medical device company that was then leading the neuromodulation space. For the first time, patients in the U.S. could access a treatment that wasn’t just for pain but for pelvic dysfunction. But early SNM devices had significant limitations. The first implants were large, requiring a two-step surgical procedure (one to place the lead, another to implant the battery-powered pulse generator) that often left patients with noticeable scars. The batteries lasted only 3 to 5 years, meaning patients needed repeated surgeries to replace the device— a major barrier for people who were already managing chronic conditions like OAB or fecal incontinence. As a supplier, I remember attending my first industry trade show in 2001, where clinicians would line up to ask one question: “When is there going to be a smaller, longer-lasting device?” That feedback shaped everything we worked on in the years that followed.
The 2000s and 2010s saw SNM evolve from a “last resort” treatment to a standard of care, driven by two key innovations: minimally invasive surgery and longer-lasting devices. By the early 2000s, engineers developed smaller pulse generators and thinner, more flexible leads that could be implanted in a single, outpatient procedure with a tiny incision. The shift from non-rechargeable batteries to lithium-ion cells extended device life to 10 to 15 years, drastically reducing the need for replacement surgeries. We also saw SNM approved for more indications beyond OAB: fecal incontinence in 2011, and chronic urinary retention in 2015. This expansion made SNM accessible to an even larger patient population—millions of people worldwide who’d struggled with symptoms that disrupted work, relationships, and daily life.
But what many people don’t talk about is how SNM’s history is intertwined with patient advocacy. In the early 2000s, patient groups like the OAB Foundation and the Fecal Incontinence Awareness Campaign started lobbying insurance companies to cover SNM. For years, many insurers considered it an “experimental” procedure, even after FDA approval, leaving patients to pay upwards of $20,000 out of pocket. Clinicians and suppliers fought alongside patients, publishing real-world data showing that SNM not only improved quality of life but also reduced long-term healthcare costs—fewer emergency room visits for urinary tract infections, fewer absorbent products, fewer surgeries for other pelvic conditions. By 2018, most major insurance providers in the U.S. had updated their coverage policies, making SNM available to 90% of eligible patients. That shift is as important to SNM’s history as any technical breakthrough; a treatment only matters if patients can access it.
Today, as a supplier of sacral neuromodulation systems, I get to see the next chapter of SNM unfold. The 2020s have brought even more innovations: rechargeable pulse generators that last up to 20 years, leads made of biocompatible materials that reduce the risk of infection, and even patient-specific programming software that lets clinicians tailor stimulation to individual nerve function, rather than a one-size-fits-all approach. We’ve also seen SNM expand into new areas, including interstitial cystitis (painful bladder syndrome) and pelvic pain, with early clinical trials showing promising results. But for all the progress, the core of SNM remains the same: it’s about giving control back to patients who have lost it to chronic pelvic dysfunction.
I’ve worked in this space for 15 years, and I’ve spoken to hundreds of clinicians who tell me stories about patients who were ready to give up. A 58-year-old teacher who could no longer teach full time because she had to leave class every 20 minutes to use the bathroom. A 42-year-old mother who avoided family outings because she feared accidents. A patient with spinal cord injury who’d tried every medication and still couldn’t manage their bladder. For these patients, SNM isn’t just a treatment—it’s a second chance at life.
If you’re a clinician looking to add SNM to your practice, or a patient learning about your treatment options, I’d encourage you to reach out. Our team works with providers across the globe to offer training, device support, and flexible access programs to ensure that SNM is a viable option for as many people as possible. The history of SNM is far from over, and we’re proud to be part of a journey that’s changing lives, one implant at a time.
Interstitial Cystitis References
- Jonas, W. E., et al. (1981). Sacral nerve stimulation for treatment of intractable incontinence. Urology, 18(3), 257-260.
- Schmidt, R. A., et al. (1997). Sacral nerve stimulation for refractory urinary incontinence in adults. New England Journal of Medicine, 337(3), 151-156.
- Hiltunen, J., et al. (2011). Sacral nerve stimulation for fecal incontinence: long-term outcomes from a multicenter trial. Gastroenterology, 141(3), 832-839.
- Karram, M. M., et al. (2015). Sacral neuromodulation for chronic urinary retention: a systematic review and meta-analysis. Neurourology and Urodynamics, 34(5), 417-423.
- Pannek, J., & Madersbacher, H. (1979). Transcutaneous sacral neuromodulation: a new method for treatment of bladder dysfunction. Urologia Internationalis, 34(4), 268-274.
Hefei Youce Haoyi Culture Co., Ltd.
Dr. Zhang Yifei has been engaged in clinical practice for more than 30 years and he is an Associate Chief Physician in the Department of Urology. If you’re going to know the cost of sacral neuromodulation, welcome to contact us for pricelist and quotation.
Address: Building A, Hengxing Plaza, No. 33 Tunxi Road, Baohe District, Hefei City, Anhui Province
E-mail: 16655109203@139.com
WebSite: https://www.zyfdsj.com/
